The diagnostic path to Pompe disease

Olaf A. Bodamer, Christina Y. Hung

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pompe disease (PD) is a lysosomal disease that primarily affects skeletal and smooth muscles due to a deficiency of acid alpha glucosidase. The resulting clinical phenotype reflects a continuum ranging from severe infantile to later onset forms of PD. Early diagnosis is essential to prevent long-term complications and/or disease progression through initiation of enzyme-replacement therapy. The diagnostic path to PD starts with the ascertainment of medical and family history as well as an in-depth clinical and neurologic evaluation. The involvement of proximal muscle groups including hip and thigh muscles as well as the diaphragm is characteristic for later onset PD. Once PD is considered creatine kinase (CK) should be measured, realizing that levels may be within normal limits in end stage disease. Ultimately, diagnostic confirmation is readily achieved by enzyme analysis in dried blood spots and/or leukocytes followed by molecular analysis. Muscle biopsy is not sensitive enough for diagnostic testing of PD but may be an important diagnostic test for the differential diagnosis of myopathies. Future diagnostic approaches include whole exome and genome sequencing, which may contribute to our understanding of genotype-phenotype correlation and phenotype prediction.

Original languageEnglish
Pages (from-to)83-86
Number of pages4
JournalEuropean Neurological Review
Volume9
Issue number1
StatePublished - Jan 1 2014

Fingerprint

Glycogen Storage Disease Type II
Muscles
Dried Blood Spot Testing
Medical History Taking
Exome
Enzyme Replacement Therapy
Phenotype
Genetic Association Studies
Muscular Diseases
Creatine Kinase
Thigh
Diaphragm
Routine Diagnostic Tests
Nervous System
Smooth Muscle
Disease Progression
Hip
Early Diagnosis
Skeletal Muscle
Leukocytes

Keywords

  • Alpha glucosidase
  • Diagnosis
  • Dried blood spot
  • Glycogen storage disease II
  • Laboratory testing
  • Pompe disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Bodamer, O. A., & Hung, C. Y. (2014). The diagnostic path to Pompe disease. European Neurological Review, 9(1), 83-86.

The diagnostic path to Pompe disease. / Bodamer, Olaf A.; Hung, Christina Y.

In: European Neurological Review, Vol. 9, No. 1, 01.01.2014, p. 83-86.

Research output: Contribution to journalArticle

Bodamer, OA & Hung, CY 2014, 'The diagnostic path to Pompe disease', European Neurological Review, vol. 9, no. 1, pp. 83-86.
Bodamer OA, Hung CY. The diagnostic path to Pompe disease. European Neurological Review. 2014 Jan 1;9(1):83-86.
Bodamer, Olaf A. ; Hung, Christina Y. / The diagnostic path to Pompe disease. In: European Neurological Review. 2014 ; Vol. 9, No. 1. pp. 83-86.
@article{40659ba9940742768166f83fbdf178e0,
title = "The diagnostic path to Pompe disease",
abstract = "Pompe disease (PD) is a lysosomal disease that primarily affects skeletal and smooth muscles due to a deficiency of acid alpha glucosidase. The resulting clinical phenotype reflects a continuum ranging from severe infantile to later onset forms of PD. Early diagnosis is essential to prevent long-term complications and/or disease progression through initiation of enzyme-replacement therapy. The diagnostic path to PD starts with the ascertainment of medical and family history as well as an in-depth clinical and neurologic evaluation. The involvement of proximal muscle groups including hip and thigh muscles as well as the diaphragm is characteristic for later onset PD. Once PD is considered creatine kinase (CK) should be measured, realizing that levels may be within normal limits in end stage disease. Ultimately, diagnostic confirmation is readily achieved by enzyme analysis in dried blood spots and/or leukocytes followed by molecular analysis. Muscle biopsy is not sensitive enough for diagnostic testing of PD but may be an important diagnostic test for the differential diagnosis of myopathies. Future diagnostic approaches include whole exome and genome sequencing, which may contribute to our understanding of genotype-phenotype correlation and phenotype prediction.",
keywords = "Alpha glucosidase, Diagnosis, Dried blood spot, Glycogen storage disease II, Laboratory testing, Pompe disease",
author = "Bodamer, {Olaf A.} and Hung, {Christina Y.}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "9",
pages = "83--86",
journal = "European Neurological Review",
issn = "1758-3837",
publisher = "Touch Briefings",
number = "1",

}

TY - JOUR

T1 - The diagnostic path to Pompe disease

AU - Bodamer, Olaf A.

AU - Hung, Christina Y.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pompe disease (PD) is a lysosomal disease that primarily affects skeletal and smooth muscles due to a deficiency of acid alpha glucosidase. The resulting clinical phenotype reflects a continuum ranging from severe infantile to later onset forms of PD. Early diagnosis is essential to prevent long-term complications and/or disease progression through initiation of enzyme-replacement therapy. The diagnostic path to PD starts with the ascertainment of medical and family history as well as an in-depth clinical and neurologic evaluation. The involvement of proximal muscle groups including hip and thigh muscles as well as the diaphragm is characteristic for later onset PD. Once PD is considered creatine kinase (CK) should be measured, realizing that levels may be within normal limits in end stage disease. Ultimately, diagnostic confirmation is readily achieved by enzyme analysis in dried blood spots and/or leukocytes followed by molecular analysis. Muscle biopsy is not sensitive enough for diagnostic testing of PD but may be an important diagnostic test for the differential diagnosis of myopathies. Future diagnostic approaches include whole exome and genome sequencing, which may contribute to our understanding of genotype-phenotype correlation and phenotype prediction.

AB - Pompe disease (PD) is a lysosomal disease that primarily affects skeletal and smooth muscles due to a deficiency of acid alpha glucosidase. The resulting clinical phenotype reflects a continuum ranging from severe infantile to later onset forms of PD. Early diagnosis is essential to prevent long-term complications and/or disease progression through initiation of enzyme-replacement therapy. The diagnostic path to PD starts with the ascertainment of medical and family history as well as an in-depth clinical and neurologic evaluation. The involvement of proximal muscle groups including hip and thigh muscles as well as the diaphragm is characteristic for later onset PD. Once PD is considered creatine kinase (CK) should be measured, realizing that levels may be within normal limits in end stage disease. Ultimately, diagnostic confirmation is readily achieved by enzyme analysis in dried blood spots and/or leukocytes followed by molecular analysis. Muscle biopsy is not sensitive enough for diagnostic testing of PD but may be an important diagnostic test for the differential diagnosis of myopathies. Future diagnostic approaches include whole exome and genome sequencing, which may contribute to our understanding of genotype-phenotype correlation and phenotype prediction.

KW - Alpha glucosidase

KW - Diagnosis

KW - Dried blood spot

KW - Glycogen storage disease II

KW - Laboratory testing

KW - Pompe disease

UR - http://www.scopus.com/inward/record.url?scp=84904692180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904692180&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84904692180

VL - 9

SP - 83

EP - 86

JO - European Neurological Review

JF - European Neurological Review

SN - 1758-3837

IS - 1

ER -